# To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594

> **NCT01636024** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 73 (actual)

## Conditions studied

- Safety
- Pharmacokinetics
- Pharmacodynamics of AZD7594

## Interventions

- **DRUG:** AZD7594
- **DRUG:** Placebo to match

## Key facts

- **NCT ID:** NCT01636024
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2013-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01636024

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01636024, "To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01636024. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*